Biopharmaceutics & Drug Disposition最新文献

Influences of Magnesium Isoglycyrrhizinate on the Pharmacokinetics of Almonertinib in Rats and Its Potential Mechanisms. 异甘草酸镁对阿莫那替尼大鼠药动学的影响及其可能机制。

IF 1.7 4区医学

Biopharmaceutics & Drug Disposition Pub Date : 2025-05-07 DOI: 10.1002/bdd.70007

Yuhao Fu, Ying Li, Yajing Li, Xueru He, Xuejiao Xun, Zhanjun Dong

{"title":"Influences of Magnesium Isoglycyrrhizinate on the Pharmacokinetics of Almonertinib in Rats and Its Potential Mechanisms.","authors":"Yuhao Fu, Ying Li, Yajing Li, Xueru He, Xuejiao Xun, Zhanjun Dong","doi":"10.1002/bdd.70007","DOIUrl":"https://doi.org/10.1002/bdd.70007","url":null,"abstract":"<p><p>Almonertinib has been approved for the first-line therapy of advanced epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). As a hepatoprotective agent, magnesium isoglycyrrhizinate (MgIG) was widely used in the treatment of drug-induced liver injury. Although Almonertinib is commonly prescribed in combination with MgIG in clinical application, the interaction research between them has not been reported. This research was conducted to explore the influences of MgIG on the pharmacokinetics of Almonertinib in rats and to investigate its possible molecular mechanisms. The plasma concentration of Almonertinib in male Sprague-Dawley (SD) rats was determined by ultra-performance liquid chromatography-tandem mass spectrometer (UPLC-MS/MS), the messenger RNA (mRNA) and protein expression levels of CYP3A1 (homologous to human CYP3A4) and P-glycoprotein (P-gp) in rat livers were measured by reverse transcription quantitative polymerase chain reaction (RT-qPCR) and western blot analyses. MgIG increased systemic exposure of Almonertinib significantly, resulting in increased AUC<sub>0-t</sub>, AUC<sub>0-∞</sub>, C<sub>max</sub>, and t<sub>1/2</sub>, and decreased CL<sub>z</sub>. Furthermore, MgIG can markedly down-regulate the expression levels of CYP3A1 and P-gp in rat livers. There is a drug-drug interaction (DDI) between MgIG and almonertinib, which leads to an increase of systemic exposure for almonertinib. Meanwhile, CYP3A1 and P-gp in the liver may be the primary targets of mediating the DDI, but further clinical trials are needed to confirm these results.</p>","PeriodicalId":8865,"journal":{"name":"Biopharmaceutics & Drug Disposition","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143959346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Renal Interstitial Distribution of Full-Length IgG and Fab Fragments in Unilateral Ureteral Obstruction-Induced Fibrotic Kidneys 单侧输尿管梗阻致纤维化肾间质全长IgG和Fab片段的分布

IF 1.7 4区医学

Biopharmaceutics & Drug Disposition Pub Date : 2025-04-19 DOI: 10.1002/bdd.70004

Yuki Nakamura, Kohei Togami, Sumio Chono

{"title":"Renal Interstitial Distribution of Full-Length IgG and Fab Fragments in Unilateral Ureteral Obstruction-Induced Fibrotic Kidneys","authors":"Yuki Nakamura, Kohei Togami, Sumio Chono","doi":"10.1002/bdd.70004","DOIUrl":"https://doi.org/10.1002/bdd.70004","url":null,"abstract":"<div>\u0000 \u0000 <p>Renal fibrosis, a critical contributor to chronic kidney disease, is characterized by interstitial expansion and excessive extracellular matrix accumulation. Due to their specificity, monoclonal antibodies (mAbs) and their fragments are promising candidates for treating renal fibrosis, but their distribution characteristics in fibrotic kidneys, particularly within the renal interstitium, remain unclear. This study investigated the tissue distribution of full-length IgG and Fab fragments in a unilateral ureteral obstruction (UUO)-induced renal fibrosis mouse model. Full-length IgG and Fab fragments were intravenously administered in UUO-induced renal fibrosis model mice. The concentrations in each organ and plasma were quantified using enzyme-linked immunoassay. In addition, the localization within the renal interstitium was evaluated by multiple techniques, including intravital and ex vivo confocal imaging under near-living conditions and the observation of the tissue sections via an in vivo cryotechnique. Both full-length IgG and Fab fragments showed higher distribution in fibrotic kidneys than in other organs. Specifically, Fab fragments had excellent selective accumulation in the fibrotic kidneys, whereas full-length IgG had higher absolute distribution due to slower plasma elimination. Imaging assessments revealed that both had widespread localization within the interstitial spaces of the fibrotic kidneys. Due to their superior selectivity for fibrotic kidneys, Fab fragments can be used to target fibrotic lesions. Due to its prolonged distribution, full-length IgG may offer advantages in sustained therapeutic effects. This study provides foundational insights into the distribution of mAbs and their fragments in fibrotic kidneys and underscores the importance of further pharmacokinetic analyses to refine antibody-based therapies.</p>\u0000 </div>","PeriodicalId":8865,"journal":{"name":"Biopharmaceutics & Drug Disposition","volume":"46 2","pages":"82-92"},"PeriodicalIF":1.7,"publicationDate":"2025-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143871730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Influence of a Rat Model of Depression and Gastric Ulcer on the Pharmacokinetics of Encorafenib 抑郁和胃溃疡大鼠模型对恩科非尼药代动力学的影响

IF 1.7 4区医学

Biopharmaceutics & Drug Disposition Pub Date : 2025-04-09 DOI: 10.1002/bdd.70006

Siva Nageswara Rao Gajula, Vijay Munjal, Sasikala Talari, Ziaur Rahman, Manoj P. Dandekar, Rajesh Sonti

{"title":"The Influence of a Rat Model of Depression and Gastric Ulcer on the Pharmacokinetics of Encorafenib","authors":"Siva Nageswara Rao Gajula, Vijay Munjal, Sasikala Talari, Ziaur Rahman, Manoj P. Dandekar, Rajesh Sonti","doi":"10.1002/bdd.70006","DOIUrl":"https://doi.org/10.1002/bdd.70006","url":null,"abstract":"<div>\u0000 \u0000 <p>Encorafenib is used to treat melanoma and colorectal tumors. Depression and gastric ulcer conditions can impact various physiological processes, including drug metabolism and pharmacokinetics. This study investigated the effect of a rat model of depression and gastric ulcers on the pharmacokinetics (PK) of encorafenib using the developed LC-QqQ-MS method. The chronic unpredictable mild stress (CUMS) model of depression and the indomethacin-induced gastric ulcer model were utilized to investigate the effect of depression and gastric ulcers on the pharmacokinetics of orally administered encorafenib. The focus was on parameters such as maximum plasma concentration (<i>C</i><sub>max</sub>), elimination half-life (<i>t</i><sub>1/2</sub>), mean residence time (MRT), volume of distribution (V<sub>d</sub>), area under the curve (AUC), and apparent clearance (CL/F). Rats with depression exhibited a significant increase in maximum plasma concentration (<i>C</i><sub>max</sub>). In contrast, depression led to decreased <i>t</i><sub>1/2</sub> and MRT, implying alterations in the drug's absorption and clearance. On the one hand, rats with gastric ulcers displayed a significant decrease in <i>C</i><sub>max</sub>, coupled with an extended time to reach maximum plasma concentration (<i>T</i><sub>max</sub>), prolonged <i>t</i><sub>1/2</sub>, MRT, and increased volume of distribution (Vd) of encorafenib. This preclinical study demonstrates that depression and gastric ulcers significantly impact the pharmacokinetics of encorafenib. These findings emphasize the importance of considering these disease conditions when designing encorafenib dosing regimens for optimal therapeutic outcomes in cancer patients.</p>\u0000 </div>","PeriodicalId":8865,"journal":{"name":"Biopharmaceutics & Drug Disposition","volume":"46 2","pages":"67-81"},"PeriodicalIF":1.7,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143871448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Novel Enteric Microsphere of Beclomethasone Dipropionate With Colon Delivery and Enhancement of Anti-Inflammatory Effects 新型肠用二丙酸倍氯米松微球结肠给药及增强抗炎作用。

IF 1.7 4区医学

Biopharmaceutics & Drug Disposition Pub Date : 2025-04-09 DOI: 10.1002/bdd.70005

Atsushi Uchida, Yuto Hayashi, Tsubasa Kihara, Kohei Yamada, Hideyuki Sato, Satomi Onoue

{"title":"Novel Enteric Microsphere of Beclomethasone Dipropionate With Colon Delivery and Enhancement of Anti-Inflammatory Effects","authors":"Atsushi Uchida, Yuto Hayashi, Tsubasa Kihara, Kohei Yamada, Hideyuki Sato, Satomi Onoue","doi":"10.1002/bdd.70005","DOIUrl":"10.1002/bdd.70005","url":null,"abstract":"<div>\u0000 \u0000 <p>The present study aimed to develop a novel colon-targeting microsphere of beclomethasone dipropionate (cMS/BDP) with enhanced pharmacological effect of BDP in the colon. cMS/BDP was prepared using Eudragit<sup>®</sup> S-100 by the emulsion solvent diffusion method, and its physicochemical properties were characterized. A pharmacokinetic study was conducted to assess systemic exposure and colon distribution of BDP after oral administration of cMS/BDP to rats. A pharmacodynamic study was carried out to evaluate the anti-inflammatory effect of cMS/BDP after its oral administration to ulcerative colitis model rats. The particle size of cMS/BDP was calculated to be ca. 20 μm, and most BDP in cMS/BDP might be in an amorphous state. In dissolution tests, cMS/BDP showed pH-dependent release behavior of BDP and marked BDP release at pH 7.4. After oral administration of cMS/BDP (5 mg-BDP/kg) to rats, BDP was rapidly metabolized to beclomethasone 17-monopropionate (17-BMP, a BDP metabolite) in the gastrointestinal tract and liver, and relative oral bioavailability of 17-BMP in the cMS/BDP group was calculated to be ca. 4.8% compared with that in the BDP solution group. The tissue-to-plasma partition coefficient value, an index of colon distribution, for cMS/BDP was found to be 15-fold higher than that for BDP solution. In the cMS/BDP (50 μg/kg) group, colonic myeloperoxidase activity and hyperplasia of the submucosa were negligibly elevated. From these findings, the cMS approach for BDP would be a promising dosage option for strategic colon delivery, leading to an improved therapeutic potential of BDP with a wide safety margin.</p>\u0000 </div>","PeriodicalId":8865,"journal":{"name":"Biopharmaceutics & Drug Disposition","volume":"46 2","pages":"58-66"},"PeriodicalIF":1.7,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143810174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Species Differences in Carboxylesterases Among Humans, Cynomolgus Monkeys, and Mice in the Hydrolysis of Atorvastatin Derivatives 人类、食蟹猴和小鼠中羧酸酯酶水解阿托伐他汀衍生物的物种差异。

IF 1.7 4区医学

Biopharmaceutics & Drug Disposition Pub Date : 2025-03-24 DOI: 10.1002/bdd.70003

Masato Takahashi, Sachiko Sakai, Kohei Takahashi, Masakiyo Hosokawa

{"title":"Species Differences in Carboxylesterases Among Humans, Cynomolgus Monkeys, and Mice in the Hydrolysis of Atorvastatin Derivatives","authors":"Masato Takahashi, Sachiko Sakai, Kohei Takahashi, Masakiyo Hosokawa","doi":"10.1002/bdd.70003","DOIUrl":"10.1002/bdd.70003","url":null,"abstract":"<div>\u0000 \u0000 <p>Nonclinical trials are crucial for assessing pharmaceutical efficacy and safety prior to clinical trials. However, disparities in drug metabolism between humans and animals complicate extrapolating animal data to humans. Variability in drug-metabolizing enzymes, such as carboxylesterases (CESs), contributes to differences in drug kinetics. This study aimed to explore species disparities in CES substrate specificity among humans (hCES1), mice (mCES1), and cynomolgus monkeys (mfCES1) using diverse atorvastatin ester derivatives. This study measured hydrolysis rates of 30 atorvastatin derivatives. Metabolites were identified via HPLC with an internal standard, measuring rates per unit time and enzyme amount. Enzyme metabolic activity was compared using hydrolysis rates. The structure of the alkoxy group resulted in differences ranging from approximately half to 8.97-fold between hCES1 and mCES1 and differences ranging from similar to 15.82-fold between hCES1 and mfCES1. Caution is warranted when extrapolating animal data to humans, especially for esters with diverse structures. Our focus on the alkoxy group structure highlights its impact on hydrolysis rates. Further investigation into species differences among CES enzymes is essential for accurate translational research.</p>\u0000 </div>","PeriodicalId":8865,"journal":{"name":"Biopharmaceutics & Drug Disposition","volume":"46 2","pages":"49-57"},"PeriodicalIF":1.7,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143699209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An Optimised Mobilenet V2 Attention Parallel Network for Predicting Drug–Drug Interactions Through Combining Local and Global Features 结合局部和全局特征预测药物-药物相互作用的优化Mobilenet V2注意力并行网络。

IF 1.7 4区医学

Biopharmaceutics & Drug Disposition Pub Date : 2025-03-12 DOI: 10.1002/bdd.70001

S. K. Mydhili, S. Nithyaselvakumari, K. Padmanaban, D. Karunkuzhali

{"title":"An Optimised Mobilenet V2 Attention Parallel Network for Predicting Drug–Drug Interactions Through Combining Local and Global Features","authors":"S. K. Mydhili, S. Nithyaselvakumari, K. Padmanaban, D. Karunkuzhali","doi":"10.1002/bdd.70001","DOIUrl":"10.1002/bdd.70001","url":null,"abstract":"<div><p>Drug–drug interactions (DDIs) are an important concern in the clinical practice and drug development process as these may lead to serious adverse effects on patient safety. Thorough DDI prediction is important for effective medication management and reduced risk factors. This work presents a new technique, namely MV2SAPCNNO: MobileNetV2 with simplicial attention network-based parallel convolutional neural network and narwhal optimiser, for improving the precision of DDI prediction. The proposed method starts with data preprocessing, including normalisation and noise reduction, to enhance the quality of the data. Then, MobileNetV2 with simplicial attention network (MV2SAN) is used to extract both local and global features from the dataset. These features are processed using a parallel convolutional neural network (PCNN), optimised by the narwhal optimiser (NO) to improve parameter tuning, minimise error and reduce computational complexity. The performance of the model is evaluated using accuracy, precision, recall and F-score. Experimental results prove that MV2SAPCN-NO achieves better performance over the current models of DDI prediction in accuracy and enhanced classification metrics. The narwhal optimiser enhances the model's convergence efficiency and decreases computational time with an excellent predictive performance. An efficient and accurate DDI prediction model was proposed called MV2SAPCNNO. This model actually outperformed traditional models, and such findings were exhibited to contribute towards secure medication administration, drug development processes and protection of patients in clinical practice.</p></div>","PeriodicalId":8865,"journal":{"name":"Biopharmaceutics & Drug Disposition","volume":"46 1","pages":"22-32"},"PeriodicalIF":1.7,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143603838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pregnenolone Sulfate Permeation at the Blood–Brain Barrier is Independent of OATP2B1—In Vivo and In Vitro Insights 孕烯醇酮硫酸盐在血脑屏障的渗透是独立于oatp2b1 -体内和体外的见解。

IF 1.7 4区医学

Biopharmaceutics & Drug Disposition Pub Date : 2025-03-12 DOI: 10.1002/bdd.70002

Valerio Taggi, Anima M. Schäfer, Stefan Oswald, Jonny Hanna Kinzi, Isabell Seibert, Alaa Al-Khatib, Henriette E. Meyer zu Schwabedissen

{"title":"Pregnenolone Sulfate Permeation at the Blood–Brain Barrier is Independent of OATP2B1—In Vivo and In Vitro Insights","authors":"Valerio Taggi, Anima M. Schäfer, Stefan Oswald, Jonny Hanna Kinzi, Isabell Seibert, Alaa Al-Khatib, Henriette E. Meyer zu Schwabedissen","doi":"10.1002/bdd.70002","DOIUrl":"10.1002/bdd.70002","url":null,"abstract":"<div>\u0000 \u0000 <p>Sulfated steroids such as pregnenolone sulfate (PregS) are important for neuronal development and cognitive functions. Given the hydrophilic sulfate moiety, it is assumed that PregS requires an active transport mechanism to cross the blood–brain barrier (BBB). The human organic anion transporting polypeptide (OATP)2B1 has been previously shown to transport sulfated steroids and is therefore a proposed candidate for the transport of PregS. In this study, we aimed to investigate the role of OATP2B1 in the uptake of PregS in the brain. Tritium-labeled PregS was intravenously administered to humanized (<i>SLCO2B1</i><sup><i>+/+</i></sup>), knockout (<i>rSlco2b1</i><sup><i>−/−</i></sup>), and wildtype (WT) rats. Accumulation of the radiotracer was analyzed in rat brain, liver, small intestine, kidney, heart, and muscle. Moreover, transporter expression in brain microvessels was assessed through targeted proteomics and Western blot analysis. The involvement of hOATP2B1 in PregS transport across the BBB was further studied using a hBMEC-based in vitro BBB model. Our results indicated no significant difference in accumulation of the radiotracer among the different rat genotypes in the brain or in other tissues. In line with what we observed in the rat model, the subsequent in vitro study showed no involvement of hOATP2B1 in the transport of PregS. Taken together, our findings highlight the species-specific differences in transporter expression and suggest that OATP2B1 does not mediate PregS uptake across the BBB.</p>\u0000 </div>","PeriodicalId":8865,"journal":{"name":"Biopharmaceutics & Drug Disposition","volume":"46 1","pages":"33-46"},"PeriodicalIF":1.7,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143603839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nanostructured Lipid Carriers-Based Topical Gel of Betulinic Acid: In Vitro, In Vivo Evaluation and Dermatokinetic Analysis 基于纳米结构脂质载体的白桦酸局部凝胶：体外、体内评价和皮肤动力学分析。

IF 1.7 4区医学

Biopharmaceutics & Drug Disposition Pub Date : 2025-03-04 DOI: 10.1002/bdd.70000

Xin Wang, Yangnan Chen, Yan Liu, Danqing Wu, Yanqiu Long, Shuangying Gui, Zhiyun Zheng, Ning He

{"title":"Nanostructured Lipid Carriers-Based Topical Gel of Betulinic Acid: In Vitro, In Vivo Evaluation and Dermatokinetic Analysis","authors":"Xin Wang, Yangnan Chen, Yan Liu, Danqing Wu, Yanqiu Long, Shuangying Gui, Zhiyun Zheng, Ning He","doi":"10.1002/bdd.70000","DOIUrl":"10.1002/bdd.70000","url":null,"abstract":"<div>\u0000 \u0000 <p>The aim of this study was to improve the penetration of betulinic acid (BA) into skin efficiently by incorporating it into a nanostructured lipid carrier (NLC)-based gel. BA-NLC was prepared by the melt-emulsification and low-temperature solidification method. The optimized formulation was incorporated into the hydrogel and evaluated for pH, in vitro release, occlusion factor, and dermatokinetics. Furthermore, the transdermal penetration mechanism of the NLC gel was investigated by Fourier transform infrared spectroscopy (FT-IR), differential scanning calorimetry (DSC), skin histological staining, and fluorescence microscopic methods. The optimized NLC showed a particle size of 153.40 nm and a high <i>EE</i> of 86.21%. In vitro drug release behavior of the BA-NLC gel showed higher cumulative release at 24 h (67.17 ± 2.39%) compared to the free drug (57.53 ± 2.17%). In vivo dermatokinetic studies disclosed that the BA-NLC gel presented elevated <i>C</i><sub>max</sub> and <i>AUC</i><sub>0–24</sub> in the epidermis and dermis in contrast to the conventional gel. FT-IR and DSC research indicated that the NLC formulations changed the configuration of skin keratin and augmented lipid fluidity, thus facilitating the percutaneous permeability of actives. Fluorescence microscopy also indicated improved skin penetration of the BA-NLC gel. Hence, the optimized NLC gel could potentially be a promising drug nanocarrier to boost skin drug penetration and retention.</p>\u0000 </div>","PeriodicalId":8865,"journal":{"name":"Biopharmaceutics & Drug Disposition","volume":"46 1","pages":"10-21"},"PeriodicalIF":1.7,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143555788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

In Vivo Animal Spices and Experimental Technique to Evaluate Sustained Release Granules 动物体内香料和实验技术评价缓释颗粒。

IF 1.7 4区医学

Biopharmaceutics & Drug Disposition Pub Date : 2025-01-02 DOI: 10.1002/bdd.2407

Masateru Miyake, Mayumi Kano, Yuji Suzuki, Masami Kato, Tadashi Mukai

{"title":"In Vivo Animal Spices and Experimental Technique to Evaluate Sustained Release Granules","authors":"Masateru Miyake, Mayumi Kano, Yuji Suzuki, Masami Kato, Tadashi Mukai","doi":"10.1002/bdd.2407","DOIUrl":"10.1002/bdd.2407","url":null,"abstract":"<div>\u0000 \u0000 <p>Establishment of a suitable animal model to evaluate sustained release (SR) formulations is very important because it reduces the development time of SR formulations. Beagle dogs are often used to evaluate prototype formulations since they can be directly administered powder, such as drug substance. However, the physiological condition of dogs is very different to that of humans. Therefore, the benefits of utilizing beagle dogs for the evaluation of modified release formulations such as sustained release formulations and enteric-coated formulations are doubtful. To clarify the best animal and/or experimental technique for the evaluation of modified release formulations, we investigated dipyridamole pharmacokinetics from prototype sustained release granules by utilizing beagle dogs, propantheline bromide-treated (PBT) beagle dogs, and miniature pigs. In normal dogs, the intestinal absorption and sustained release effect of dipyridamole decreased in the 20 mg sustained release granule. However, in PBT dogs, a sustained release effect was observed in the 45 mg sustained release granule, and its bioavailability was also maintained. Accordingly, PBT dogs could be the best to evaluate sustained release formulations such as tablets and granules, and the use of miniature pigs might be better to evaluate granules with equal to or less than 1 mm diameter.</p>\u0000 </div>","PeriodicalId":8865,"journal":{"name":"Biopharmaceutics & Drug Disposition","volume":"46 1","pages":"3-9"},"PeriodicalIF":1.7,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142920586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Application of Physiologically Based Pharmacokinetic Model to Compare the Biodistribution of Liposomal Amphotericin B With Conventional Amphotericin B Deoxycholate in Humans 应用生理药代动力学模型比较两性霉素B脂质体与常规两性霉素B脱氧胆酸盐在人体内的生物分布。

IF 1.7 4区医学

Biopharmaceutics & Drug Disposition Pub Date : 2024-12-25 DOI: 10.1002/bdd.2406

Xueyuan Zhang, Yingying Yang, Manman Wang, Huanhuan Qi, Chunlei Li, Limei Zhao

{"title":"Application of Physiologically Based Pharmacokinetic Model to Compare the Biodistribution of Liposomal Amphotericin B With Conventional Amphotericin B Deoxycholate in Humans","authors":"Xueyuan Zhang, Yingying Yang, Manman Wang, Huanhuan Qi, Chunlei Li, Limei Zhao","doi":"10.1002/bdd.2406","DOIUrl":"10.1002/bdd.2406","url":null,"abstract":"<div>\u0000 \u0000 <p>Amphotericin B (AmB) has been a cornerstone in the treatment of invasive fungal infections for over 6 decades. Compared with conventional amphotericin B deoxycholate (AmB-DOC), liposomal amphotericin B has comparable efficacy but less nephrotoxicity. The main purpose of this study was to investigate the reason why liposomal amphotericin B has similar therapeutic effects but lower toxicity and the differences of distribution in humans between liposomal amphotericin B and AmB-DOC. To compare the distribution of liposomal amphotericin B and AmB-DOC in humans, the physiologically based pharmacokinetic (PBPK) model was established by bottom-up stepwise method. A rat PBPK model was established firstly, then verified in mouse level in consideration of interspecies differences in physiological- and drug-specific parameters, and finally the PBPK model was extrapolated to humans. Based on preclinical and clinical pharmacokinetic (PK) studies, the AmB-DOC and liposomal amphotericin B PBPK model were established, respectively. The simulated results of human PBPK model showed that the liposomal formulation changed the pharmacokinetic characteristics of AmB. Compared with AmB-DOC, the plasma exposure of liposomal formulation was higher, but the renal exposure was significantly reduced.</p>\u0000 </div>","PeriodicalId":8865,"journal":{"name":"Biopharmaceutics & Drug Disposition","volume":"45 4-6","pages":"208-219"},"PeriodicalIF":1.7,"publicationDate":"2024-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142891846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0